SCHEDULE 13G/A: BlackRock Amends Stake in Protagonist Therapeutics, Disclosing 14.8% Beneficial Ownership

BlackRock, Inc. has filed an amendment to its Schedule 13G, revealing a 14.8% beneficial ownership stake in Protagonist Therapeutics, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. has filed Amendment No. 6 to its Schedule 13G regarding its beneficial ownership in Protagonist Therapeutics, Inc.
• As of March 31, 2025, BlackRock, Inc. beneficially owns an aggregate of 9,084,682 shares of Protagonist Therapeutics' Common Stock.
• This ownership represents 14.8% of the class of securities.
• BlackRock holds sole voting power over 9,025,847 shares and sole dispositive power over 9,084,682 shares.
• No shared voting or dispositive power is reported.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• One of BlackRock's entities, iShares Core S&P Small-Cap ETF, is noted to have an interest of more than five percent in the common stock of Protagonist Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as a large institutional investor maintaining a significant stake can be seen as a sign of confidence, although the filing itself is purely factual and does not contain performance-related information.

Positives

• The disclosure of a significant 14.8% stake by a major institutional investor like BlackRock can be interpreted as a vote of confidence in Protagonist Therapeutics, Inc.

Negatives

• NA

Risks

• NA

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Protagonist Therapeutics, Inc. or BlackRock regarding the issuer's future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Certification by Spencer Fleming, Managing Director of BlackRock, Inc.)

Industry Context

This filing is a routine disclosure by a major institutional investor, BlackRock, Inc., indicating its passive ownership stake in Protagonist Therapeutics, Inc., a biotechnology company. Such filings are common and provide transparency into significant institutional holdings, which can influence market perception and liquidity for the underlying stock. The 14.8% stake signifies a substantial, but non-controlling, investment by one of the world's largest asset managers.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by BlackRock may enhance investor confidence and potentially improve liquidity for Protagonist Therapeutics' stock.
• Company Management: Awareness of a large, passive institutional holder like BlackRock may influence strategic decisions, though BlackRock explicitly states its intent is not to influence control.

Key Dates

Keywords

BlackRock, Protagonist Therapeutics, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management, Pharmaceuticals, Biotechnology